Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer

References

• BreastCancer.Org [webpage on the Internet]US Breast Cancer Statisctics2016 Available from: http://www.breastcancer.org/symptoms/understand_bc/statisticsAccessed December 11, 2016
   Google Scholar
• NakadaHNakagomiHHirotsuYA study of tumor heterogeneity in a case with breast cancerBreast Cancer201724348348927687626
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• TacarOSriamornsakPDassCRDoxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systemsJ Pharm Pharmacol201365215717023278683
   PubMed Web of Science ®Google Scholar
• GabizonAAPatilYLa-BeckNMNew insights and evolving role of pegylated liposomal doxorubicin in cancer therapyDrug Resist Updat2016299010627912846
   PubMed Web of Science ®Google Scholar
• OttMRobertsonJDGogvadzeVZhivotovskyBOrreniusSCytochrome c release from mitochondria proceeds by a two-step processProc Natl Acad Sci U S A20029931259126311818574
   PubMed Web of Science ®Google Scholar
• ShanKLincoffAMYoungJBAnthracycline-induced cardiotoxicityAnn Intern Med1996125147588644988
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsCancer200397112869287912767102
   PubMed Web of Science ®Google Scholar
• BriaECupponeFFornierMCardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trialsBreast Cancer Res Treat2008109223123917638068
   PubMed Web of Science ®Google Scholar
• LaoJMadaniJPuértolasTLiposomal doxorubicin in the treatment of breast cancer patients: a reviewJ Drug Deliv2013201345640945641223634302
   PubMedGoogle Scholar
• JanssenCaelyx Product Monograph2011 Available from: https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/caelyx_cpm.pdfAccessed August 20, 2018
   Google Scholar
• MinchintonAITannockIFDrug penetration in solid tumoursNat Rev Cancer20066858359216862189
   PubMed Web of Science ®Google Scholar
• NicholsJWBaeYHEPR: evidence and fallacyJ Control Release201419045146424794900
   PubMed Web of Science ®Google Scholar
• HilmerSNCoggerVCMullerMLe CouteurDGThe hepatic pharmacokinetics of doxorubicin and liposomal doxorubicinDrug Metab Dispos200432879479915258103
   PubMed Web of Science ®Google Scholar
• RiveraELiposomal anthracyclines in metastatic breast cancer: clinical updateOncologist20038suppl 239
   Google Scholar
• O’BrienMEWiglerNInbarMCAELYX Breast Cancer Study GroupReduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerAnn Oncol200415344044914998846
   PubMed Web of Science ®Google Scholar
• Doxil - Dosing for progressed or recurrent ovarian cancer [webpage on the Internet]Janssen Products, LP2018 Available from: https://www.doxil.com/hcp/progressed-or-recurrent-ovarian-cancer/Accessed August 20, 2018
   Google Scholar
• FDA Approves Supplemental New Drug Application for DOXIL [webpage on the Internet]ManchesterNews Medical Life Sciences2009 Available from: http://www.news-medical.net/news/20090910/FDA-approves-Supplemental-New-Drug-Application-for-DOXIL.aspxAccessed August 20, 2018
   Google Scholar
• EspelinCWLeonardSCGerettiEWickhamTJHendriksBSDual HER2 Targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancerCancer Res20167661517152726759238
   PubMed Web of Science ®Google Scholar
• RafiyathSMRasulMLeeBWeiGLambaGLiuDComparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisExp Hematol Oncol2012111023210520
   PubMedGoogle Scholar
• FribergLEKarlssonMOMechanistic models for myelosuppressionInvest New Drugs200321218319412889739
   PubMed Web of Science ®Google Scholar
• FribergLEHassanSBLindhagenELarssonRKarlssonMOPhar-macokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre modelEur J Pharm Sci200525116317315854812
   PubMed Web of Science ®Google Scholar
• MinamiHSasakiYSaijoNIndirect-response model for the time course of leukopenia with anticancer drugsClin Pharmacol Ther19986455115219834043
   PubMed Web of Science ®Google Scholar
• FribergLEBrindleyCJKarlssonMODevlinAJModels of schedule dependent haematological toxicity of 2’-deoxy-2’-methylidenecytidine (DMDC)Eur J Clin Pharmacol200056856757411151746
   PubMed Web of Science ®Google Scholar
• OutomuroDGranaDRAzzatoFMileiJAdriamycin-induced myocardial toxicity: new solutions for an old problem?Int J Cardiol2007117161516863672
   PubMed Web of Science ®Google Scholar
• BovelliDPlataniotisGRoilaFESMO Guidelines Working GroupCardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelinesAnn Oncol201021suppl 5v277v28220555097
   PubMed Web of Science ®Google Scholar
• MartínMSánchez-RoviraPMuñozMGEICAMPegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 studyAnn Oncol201122122591259621421542
   PubMed Web of Science ®Google Scholar
• ChiaSClemonsMMartinLAPegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trialJ Clin Oncol200624182773277816682726
   PubMed Web of Science ®Google Scholar
• ArdavanisAMavroudisDKalbakisKPegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II studyCancer Chemother Pharmacol200658674274816718470
   PubMed Web of Science ®Google Scholar
• StickelerEKlarMWatermannDPegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trialBreast Cancer Res Treat2009117359159819156515
   PubMed Web of Science ®Google Scholar
• TorrisiRCardilloACancelloGPhase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancerClin Breast Cancer201010648348821147693
   PubMed Web of Science ®Google Scholar
• GabizonACataneRUzielyBProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res19945449879928313389
   PubMed Web of Science ®Google Scholar
• SolomanRGabizonAAClinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicinClin Lymphoma Myeloma200881213218501085
   PubMedGoogle Scholar
• RomondEHJeongJHRastogiPSeven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol201230313792379922987084
   PubMed Web of Science ®Google Scholar
• Doxorubicin full prescribing information [webpage on the internet]DAILYMED Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fd148fb-0fbc-4b6f-b790-23546fb46a71#section-11.2Accessed August 20, 2018
   Google Scholar
• Doxil full prescribing information [webpage on the internet]DAILYMED Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21d9c619-7e94-49e2-ac41-31e9ea96554a#section-11.2Accessed August 20, 2018
   Google Scholar
• RochlitzCRuhstallerTLerchSSwiss Group for Clinical Cancer Research (SAKK)Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)Ann Oncol2011221808520595448
   PubMed Web of Science ®Google Scholar
• IrvinWJOrlowskiRZChiuWKPhase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancerClin Breast Cancer201010646547021147690
   PubMed Web of Science ®Google Scholar
• ColleaRPKruterFWCantrellJEPegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II studyAnn Oncol201223102599260522431702
   PubMed Web of Science ®Google Scholar
• OvermoyerBSilvermanPHolderLWTripathyDHendersonICPegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancerClin Breast Cancer20056215015716001993
   PubMedGoogle Scholar
• KurtzJERousseauFMeyerNPhase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patientsOncology2007733–421021418424884
   PubMed Web of Science ®Google Scholar
• RauKMLinYCChenYYPegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II studyBMC Cancer20151542325994543
   PubMed Web of Science ®Google Scholar
• Gil-GilMJBelletMMoralesSPegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE studyBreast Cancer Res Treat2015151359760625981896
   PubMed Web of Science ®Google Scholar
• TuxenMKColdSTangeUBBalslevENielsenDLPhase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancerActa Oncol201453101440144524991893
   PubMed Web of Science ®Google Scholar
• de La FouchardièreCLargillierRGoubelyYDocetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLEAnn Oncol200920121959196319556321
   PubMed Web of Science ®Google Scholar
• WolffACWangMLiHPhase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198Breast Cancer Res Treat2010121111112020333545
   PubMed Web of Science ®Google Scholar
• SparanoJAMakhsonANSemiglazovVFPegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III studyJ Clin Oncol200927274522452919687336
   PubMed Web of Science ®Google Scholar
• FabiAFerrettiGPapaldoPPegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patientsCancer Chemother Pharmacol200657561562316163541
   PubMed Web of Science ®Google Scholar
• RiveraEValeroVArunBPhase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancerJ Clin Oncol200321173249325412947059
   PubMed Web of Science ®Google Scholar
• AdamoVLorussoVRosselloRPegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II studyBr J Cancer200898121916192118493232
   PubMed Web of Science ®Google Scholar
• ArtioliGGraziaAMocellinSPhase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancerAnticancer Res20103093817382120944176
   PubMed Web of Science ®Google Scholar
• PircherMMlineritschBFridrikMALapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trialAnticancer Res201535151752125550597
   PubMed Web of Science ®Google Scholar
• RossiDBaldelliAMCasadeiVNeoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancerAnticancer Drugs200819773373718594216
   PubMed Web of Science ®Google Scholar
• VorobiofDARapoportBLChasenMRFirst line therapy with paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) in patients with metastatic breast cancer: a multicentre phase II studyBreast200413321922615177425
   PubMed Web of Science ®Google Scholar
• ChristodoulouCKostopoulosIKalofonosHPStudy of the Hellenic Cooperative Oncology GroupTrastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationOncology200976427528519262067
   PubMed Web of Science ®Google Scholar
• ChowLWYipAYLangBHA phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancerAm J Clin Oncol200730213313817414461
   PubMed Web of Science ®Google Scholar
• MartinMGarcía-DonasJCasadoAPhase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposureClin Breast Cancer20045535335715585072
   PubMedGoogle Scholar
• ViciPColucciGGiottaFA multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM studyJ Exp Clin Cancer Res2011303921481280
   PubMed Web of Science ®Google Scholar